Janus Henderson Group PLC Has $168.03 Million Position in Arcellx, Inc. (NASDAQ:ACLX)

Janus Henderson Group PLC lifted its stake in Arcellx, Inc. (NASDAQ:ACLX - Free Report) by 5.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,011,950 shares of the company's stock after purchasing an additional 109,332 shares during the period. Janus Henderson Group PLC owned about 3.72% of Arcellx worth $168,026,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ACLX. First Turn Management LLC acquired a new stake in shares of Arcellx during the third quarter worth about $17,896,000. Harbor Capital Advisors Inc. increased its position in shares of Arcellx by 37.0% during the third quarter. Harbor Capital Advisors Inc. now owns 27,896 shares of the company's stock worth $2,330,000 after purchasing an additional 7,534 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Arcellx during the second quarter worth about $1,494,000. Intech Investment Management LLC acquired a new stake in shares of Arcellx during the third quarter worth about $800,000. Finally, Great Point Partners LLC increased its position in Arcellx by 64.0% in the 2nd quarter. Great Point Partners LLC now owns 492,000 shares of the company's stock valued at $27,153,000 after acquiring an additional 192,000 shares during the period. 96.03% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Arcellx

In other news, Director Kavita Patel sold 15,238 shares of the firm's stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $105.92, for a total transaction of $1,614,008.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Christopher Heery sold 3,421 shares of the firm's stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $70.02, for a total transaction of $239,538.42. Following the sale, the insider now owns 9,278 shares of the company's stock, valued at approximately $649,645.56. This represents a 26.94 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 70,422 shares of company stock valued at $6,781,726. Corporate insiders own 6.24% of the company's stock.

Arcellx Price Performance

Shares of ACLX stock traded down $2.80 during trading hours on Wednesday, reaching $85.85. 340,543 shares of the company were exchanged, compared to its average volume of 477,860. Arcellx, Inc. has a fifty-two week low of $46.42 and a fifty-two week high of $107.37. The stock's fifty day moving average is $88.38 and its two-hundred day moving average is $71.01. The company has a market cap of $4.64 billion, a price-to-earnings ratio of -120.91 and a beta of 0.25.

Arcellx (NASDAQ:ACLX - Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.54) by $0.06. Arcellx had a negative net margin of 25.94% and a negative return on equity of 8.28%. The company had revenue of $26.03 million for the quarter, compared to analyst estimates of $35.21 million. On average, research analysts anticipate that Arcellx, Inc. will post -1.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

ACLX has been the topic of several research analyst reports. Morgan Stanley boosted their price target on Arcellx from $81.00 to $106.00 and gave the stock an "overweight" rating in a research note on Wednesday, November 6th. HC Wainwright boosted their price target on Arcellx from $80.00 to $95.00 and gave the company a "buy" rating in a report on Wednesday, November 6th. Bank of America upped their price objective on Arcellx from $84.00 to $100.00 and gave the stock a "buy" rating in a report on Wednesday, November 6th. Piper Sandler upped their price objective on Arcellx from $91.00 to $115.00 and gave the stock an "overweight" rating in a report on Friday, November 8th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $96.00 price target on shares of Arcellx in a report on Wednesday, November 6th. Thirteen investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $103.08.

Arcellx Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).